A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Antiviral Activity of GS-9688 in Virally-Suppressed Adult Subjects with Chronic Hepatitis B
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2018
At a glance
- Drugs GS 9688 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 10 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Sep 2018 Planned primary completion date changed from 1 Apr 2019 to 1 Mar 2019.
- 03 May 2018 Status changed from not yet recruiting to recruiting.